Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder

Sänchez‐Carbayo, Marta; Herrero, Enrique; Megías, Julián; Mira, Antonio; Soria, Federico

doi:10.1016/s0090-4295(99)00195-8

Cited by 32 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since CKs are intracellular proteins, the detection of these proteins in urine is possible only when they are released in urine following cell death. The UBC-Rapid assay is a qualitative point-of-care assay wherein CK 8 and 18 fragments present in urine react with gold-labeled antibodies forming a complex [65]. …”

Section: Urine-based Markersmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

et al. 2014

View full text Add to dashboard Cite

Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.

show abstract

Section: Urine-based Markersmentioning

confidence: 99%

“…However, it is noteworthy that barring the initial study [65], in two other studies, the overall sensitivity was less than 50% [58,59]. For UBC-ELISA, different studies have used different cutoff limits with a range of 0.16-15 μg/l.…”

Section: Urine-based Markersmentioning

confidence: 99%

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Other early assays that used an immunochromatographic technique include those for the quantification of drugs in biological fluids (100), theophylline in whole blood (57), and mouse immunoglobulin (36). Over the past decade many immunochromatographic assays have been reported for the detection of infectious diseases (2-4, 8, 9, 13, 15-17, 21, 22, 27, 29, 37, 42, 59-61, 69, 74-76, 84, 94), cancer (35,72), cardiovascular problems (54,65,66,73), pancreatitis (43), and illicit drugs (7,95). Other promising areas for the use of such assays are drug monitoring (93), food safety (10), and veterinary medicine (45,50).…”

Section: Immunochromatographic Lateral Flow Assaysmentioning

confidence: 99%

Immunological Methods for Detection and Identification of Infectious Disease and Biological Warfare Agents

Peruski

2003

Clin Vaccine Immunol

196

119

View full text Add to dashboard Cite

NATURE OF THE PROBLEMBW agents. The release of a biological weapon (BW) agent by a terrorist group or military force would likely be silent and undetectable or nearly so. As shown by anthrax attack during the fall of 2001 in the eastern United States, patients would begin appearing at hospitals and clinics within several days of exposure, most presenting with nonspecific flu-like symptoms. The first days of the outbreak might not even cause undue concern. However, depending on the type of agent and the method of dispersal, the public healthcare system would rapidly be stretched to capacity and beyond.The qualities that make a good BW agent are its relationship between aerosolization, infectivity, or toxicity and the amount of agent required to produce an effect (48). In addition, criteria such as environmental stability, ease of production, disease severity, and communicability determine which agents are the most likely to be utilized. For maximum effect, an optimal agent should be highly lethal and easily produced in large quantities and have limited options for preventive or prophylactic treatment. Given that the respiratory route is the most effective for most BW agents, stability in an aerosol form and the capability to be readily dispersed also in an aerosol (1-to 10-m particle size) are necessary. When potential agents are reviewed for these characteristics, Bacillus anthracis (anthrax) and variola major virus (smallpox) are considered to have the greatest potential for mass casualties and civil disruption. Also high on a prospective list of agents are botulinum neurotoxins, Yersinia pestis, and Francisella tularensis (48,91,92). Lower on the prospective list are Burkholderia pseudomallei and Burkholderia mallei, Rickettsia sp., Coxiella burnetii, Venezuelan equine encephalitis virus, Marburg and Ebola viruses, and influenza viruses (48,63,91,92).Emerging infectious disease agents. In addition to diseases caused by intentional epidemics, there are several emerging infectious diseases (ID) with the potential for significant public health consequences, including dengue fever, West Nile fever, and Rift Valley fever as well as the recent reemergence of malaria in the eastern United States (48,63,91,92). As with BW agents, emerging ID agents may be directly transmissible or vector borne (63). A complex interplay of factors can influence disease emergence, including genetic variation, environmental changes, and population pressures. Further compounding this already complicated situation, are the estimated 600 million international tourists annually, many with the potential to the spread disease globally in a matter of hours (63). Clearly, the challenges facing modern clinical microbiologists and immunologists are daunting enough without the added difficulties posed by the intentional release of BW/ID agents! Because of the threat posed by both BW and emerging or reemerging ID agents, there is a need to rapidly identify such agents in the clinical setting in order to treat the individuals at risk and to improve p...

show abstract

“…For example, tests are available for the detection of certain infectious diseases (17)(18)(19), cancer (20,21), cardiovascular problems (22)(23)(24), pancreatitis (25), and drugs of abuse (26,27). Other promising areas for use of such assays are drug monitoring (28), food safety (29), and veterinary medicine (30,31).…”

Section: Ucp Hold Promise For Meeting Future Needsmentioning

confidence: 99%

Upconverting Phosphor Reporters in Immunochromatographic Assays

Hampl

Hall

Mufti

et al. 2001

Analytical Biochemistry

267

201

View full text Add to dashboard Cite

Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder

Cited by 32 publications

References 21 publications

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Immunological Methods for Detection and Identification of Infectious Disease and Biological Warfare Agents

Upconverting Phosphor Reporters in Immunochromatographic Assays

Contact Info

Product

Resources

About